Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization
View ORCID ProfileTom G Richardson, Genevieve M Leyden, Qin Wang, Joshua A Bell, Benjamin Elsworth, George Davey Smith, View ORCID ProfileMichael V Holmes
doi: https://doi.org/10.1101/2021.08.06.21261699
Tom G Richardson
1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
2Novo Nordisk Research Centre, Headington, Oxford, OX3 7FZ, United Kingdom
Genevieve M Leyden
1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
3Bristol Medical School: Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, United Kingdom
Qin Wang
4MRC Population Health Research Unit (PHRU), Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, United Kingdom
Joshua A Bell
1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
Benjamin Elsworth
1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
George Davey Smith
1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
Michael V Holmes
4MRC Population Health Research Unit (PHRU), Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, United Kingdom
Data Availability
All data analysed in this study is either available from the referenced public repositories or accessible via an approved application to the UK Biobank study.
https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access
Posted August 09, 2021.
Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization
Tom G Richardson, Genevieve M Leyden, Qin Wang, Joshua A Bell, Benjamin Elsworth, George Davey Smith, Michael V Holmes
medRxiv 2021.08.06.21261699; doi: https://doi.org/10.1101/2021.08.06.21261699
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2154)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)